Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.56 |
| ▸ | ESR1 | P03372 | 11/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25836744 | 0.78 | AOC3 (0.41) | AOC3ESR1ESR2USP7JAK1 | |
| SCHEMBL21914527 | 0.78 | AOC3 (0.63) | AOC3MAOB | |
| SCHEMBL21889220 | 0.75 | DGAT1 (0.41) | AOC3ESR1ESR2USP7JAK1 | |
| SCHEMBL21889539 | 0.73 | AOC3 (1.00) | AOC3 | |
| SCHEMBL31645641 | 0.68 | ESR1 (0.45) | ESR1ESR2USP7AR | |
| SCHEMBL24407519 | 0.64 | GAA (0.40) | AOC3PDE2APDE10A | |
| SCHEMBL13926735 | 0.64 | HDAC1 (0.45) | ESR1ESR2USP7MAOB | |
| SCHEMBL29557461 | 0.64 | ESR1 (0.74) | ESR1ESR2ARMAOB | |
| SCHEMBL2862424 | 0.64 | ESR1 (0.74) | ESR1ESR2ARMAOB | |
| SCHEMBL20320451 | 0.63 | TDP2 (0.50) | AOC3TDP2PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SHANDONG DANHONG PHARMACEUTICAL CO LTD (CN) | 2021-05-11 | — | — | US | disclosed |
| US-20200115352-A1 | SSAO INHIBITOR | SHANDONG DANHONG PHARMACEUTICAL CO., LTD. | 2020-04-16 | — | — | US | disclosed |
| EP-3626699-A1 | SSAO INHIBITOR | Shandong Danhong Pharmaceutical Co., Ltd. (CN) | 2020-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001563-B2 | SSAO inhibitor | SSB, ASAH2, AOX1 | AOC3 53/4885ESR1 4721/4885ESR2 4415/4885 |
| US-20200115352-A1 | SSAO INHIBITOR | SSB, ASAH2, AOX1 | AOC3 53/4885ESR1 4721/4885ESR2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.